BeOne Medicines AG Stock Forecast

Stock Price Forecast

According to 28 analysts polled by S&P Global, BeOne Medicines AG stock has a consensus rating of "Strong Buy" and an average price target of $412.35. The average 1-year stock price forecast is 47.27% higher than the current stock price, while the lowest is $333 (+18.93%) and the highest is $501.3 (+79.04%).

Price Target: $412.35 (+47.27%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$333	$412.35	$412	$501.3
Change	+18.93%	+47.27%	+47.15%	+79.04%

Analyst Ratings

The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	18	18	18	18	19	19
Buy	7	7	7	7	8	8
Hold	0	0	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	1	1	0	0	0	0
Total	26	26	26	26	28	28

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael Schmidt Guggenheim	Guggenheim	Buy Maintains $420	Buy	Maintains	$420	+50.01%	Jun 15, 2026
Etzer Darout Barclays	Barclays	Buy Maintains $409	Buy	Maintains	$409	+46.08%	Jun 15, 2026
Yigal Nochomovitz Citi	Citi	Buy Maintains $453	Buy	Maintains	$453	+61.79%	Jun 12, 2026
Kalpit Patel Wolfe Research	Wolfe Research	Buy Maintains $340	Buy	Maintains	$340	+21.43%	Jun 3, 2026
Jessica Fye J.P. Morgan	J.P. Morgan	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 2, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

45.32B

from 37.37B

21.27%

from 37.37B

Revenue Next Year

52.00B

from 45.32B

14.74%

from 45.32B

EPS This Year

3.51

from 1.33

164.37%

from 1.33

EPS Next Year

5.37

from 3.51

52.77%

from 3.51

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	7.47B	9.77B	17.43B	27.81B	37.37B	45.32B
Revenue Growth	270.56%	30.69%	78.53%	59.51%	34.37%	21.27%
Gross Profit	6.42B	7.79B	14.74B	23.48B	32.70B	39.55B
Gross Margin	85.98%	79.77%	84.55%	84.41%	87.49%	87.28%
Operating Income	-9.14B	-12.34B	-8.56B	-4.15B	3.13B	5.98B
Net Income	-9.26B	-13.82B	-6.25B	-4.71B	2.01B	5.33B
EPS	-	-	-	-	1.33	3.51
EPS Growth	-	-	-	-	-	164.37%
Forward PE	-	-	-	-	66.95	541.77
Free Cash Flow	-7.65B	-6.51B	-9.03B	-2.71B	4.59B	4.82B
No. Analysts	-	-	-	-	-	34

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue	2026	2027	2028
High	47.9B
Avg	45.3B
Low	43.4B

Revenue Growth

Revenue Growth	2026	2027	2028
High	28.1%
Avg	21.3%
Low	16.3%

EPS Forecast

EPS	2026	2027	2028
High	5.10
Avg	3.51
Low	2.94

EPS Growth

EPS Growth	2026	2027	2028
High	283.7%
Avg	164.4%
Low	121.1%